• Eli Lilly's earnings, sales guidance for 2020 tops estimates firstwordpharma
    December 17, 2019
    Eli Lilly said Tuesday that it expects earnings per share next year in the range of $6.70 to $6.80, with overall revenue between of $23.6 billion and $24.1 billion, driven by growth from key products such as Taltz and Trulicity.
  • Gilead announces lower than expected 2017 sales guidance firstwordpharma
    February 08, 2017
    Gilead Sciences on Tuesday said that it anticipates full-year revenue for 2017 to be in the range of $22.5 billion to $24.5 billion, falling short of analysts' expectations of $27.9 billion.
PharmaSources Customer Service